HEPATOPROTECTIVE EFFECT OF LOW MOLECULAR WEIGHT MIMETICS NGF Russian patent published in 2023 - IPC A61K38/05 A61P1/16 A61P3/10 

FIELD: medicine.

SUBSTANCE: invention relates to medicine and pharmacology and concerns a means for the treatment of non-alcoholic fatty liver disease (NAFLD). The use of the low molecular weight mimetic NGF hexamethylenediamide (bis-L-monosuccinyl-L-glutamyl-L-lysine) as a treatment for NAFLD has been proposed. In an experimental model of NAFLD caused by a high-fat diet in Wistar rats, hexamethylenediamide (bis-N-monosuccinyl-L-glutamyl-L-lysine) at a dose of 5 mg/kg orally eliminates morphological disorders in the liver characteristic of NAFLD. Hexamethylenediamide (bis-N-monosuccinyl-L-glutamyl-L-lysine) reduces abdominal obesity, reduces cholesterol in the blood by 30%, triglycerides by 28% in comparison with animals on a fat diet, but not treated.

EFFECT: expansion of the arsenal of medicines for the treatment of NAFLD, obtaining a more effective, safe, non-toxic drug, suitable for oral use.

1 cl, 4 tbl, 1 dwg, 4 ex